Drugs / Hepenofovir
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04277897 | Mar → Jun 2020 | chronic hepatitis B virus infection | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06122454 | Nov 2022 → Jun 2024 | — | Xi'an Xintong Pharmaceutical Research Co.,Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hepenofovir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04277897 ↗ |
| Known as | Hepenofovir Fumarate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06122454 ↗ |
| Known as | HTS | “The goal of this a clinical trial is to learn about the efficacy，safety and Pharmacokinetics of Hepenofovir Fumarate Tablets（HTS） in patients with CHB.” NCT06122454 ↗ |
| Route | Oral | “single and multiple orally administered doses of Hepenofovir Fumarate Tablets” NCT04277897 ↗ |